Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics, Inc. (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
$2.37
$0.09(8.26%)
At close: 4:00 PM EST
$2.37
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.49 - $2.85
Previous CloseN/A
Volume293.07K
Average Volume (3M)1.97M
Market Cap
$217.75M
Enterprise Value$150.14M
Total Cash (Recent Filing)$76.94M
Total Debt (Recent Filing)$140.20K
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 25, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding91,879,170
10 Day Avg. Volume3,070,991
30 Day Avg. Volume1,973,408
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.93K
Enterprise Value/Ebitda-5.13
Forecast
1Y Price Target
$5.67Price Target Upside139.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Position And ExecutionA strong capitalization and an experienced management team support continued execution of the bispecific portfolio and ability to reach planned 2026 data readouts without immediate financing pressure.
Clinical Readouts And SafetyEarly Phase I observations showing a confirmed partial response in a heavily pre-treated ovarian cancer patient alongside no dose-limiting toxicities support the prospect of efficacy with a manageable safety profile.
Pipeline PotentialA focused pipeline of T cell engagers targeting solid tumors, including a CLDN6-directed candidate, could capture a meaningful unmet market if clinical validation confirms selectivity and tumor potency.
Bears Say
Analyst Conflicts Of InterestDisclosed commercial relationships between the research firm and covered companies introduce potential conflicts that could weaken the perceived objectivity of analyst reports and investor trust.
Clinical Data ImmaturityLimited enrollment and the preliminary nature of Phase I results create sizeable uncertainty about whether early responses will be reproducible or translate into durable clinical benefit.
Share Volatility And Valuation RiskRecent large share price swings following rapid gains highlight valuation sensitivity and raise the risk of significant downside if upcoming trial results fall short of expectations on efficacy or safety.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics, Inc.’s price range in the past 12 months?
Context Therapeutics, Inc. lowest stock price was $0.49 and its highest was $2.85 in the past 12 months.
What is Context Therapeutics, Inc.’s market cap?
Context Therapeutics, Inc.’s market cap is $217.75M.
When is Context Therapeutics, Inc.’s upcoming earnings report date?
Context Therapeutics, Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 49 days.
How were Context Therapeutics, Inc.’s earnings last quarter?
Context Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.012.
Is Context Therapeutics, Inc. overvalued?
According to Wall Street analysts Context Therapeutics, Inc.’s price is currently Undervalued.
Does Context Therapeutics, Inc. pay dividends?
Context Therapeutics, Inc. does not currently pay dividends.
What is Context Therapeutics, Inc.’s EPS estimate?
Context Therapeutics, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Context Therapeutics, Inc. have?
Context Therapeutics, Inc. has 91,879,170 shares outstanding.
What happened to Context Therapeutics, Inc.’s price movement after its last earnings report?
Context Therapeutics, Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went down -5.31%.
Which hedge fund is a major shareholder of Context Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (139.24% Upside)
$5.67 (139.24% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 680.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
159.58%
12-Months-Change
Fundamentals
Return on Equity
-33.68%
Trailing 12-Months
Asset Growth
-8.22%
Trailing 12-Months
Company Description
Context Therapeutics, Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(139.24% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.67% Mutual Funds
63.99% Other Institutional Investors
25.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---